Pregled bibliografske jedinice broj: 286641
Weekly docetaxel doses in dctx/estm therapy followed by vp-16/estm treatment in Stage D3 patients with GS>6.
Weekly docetaxel doses in dctx/estm therapy followed by vp-16/estm treatment in Stage D3 patients with GS>6. // Program Book and Abstracts, Fall Joint SBUR-ESUR Meeting, December 1-4, 2005. / Shuk-Mei Ho, PhD, Univ of Cincinnati Med Center (ur.).
Cincinnati (OH): SBUR, Society for Basic Urologic Research, 2005. str. 150-150 (poster, međunarodna recenzija, sažetak, ostalo)
CROSBI ID: 286641 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Weekly docetaxel doses in dctx/estm therapy followed by vp-16/estm treatment in Stage D3 patients with GS>6.
Autori
Tarle, Marko ; Kovačić, Ksenija ; Kraljić, Ivo.
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, ostalo
Izvornik
Program Book and Abstracts, Fall Joint SBUR-ESUR Meeting, December 1-4, 2005.
/ Shuk-Mei Ho, PhD, Univ of Cincinnati Med Center - Cincinnati (OH) : SBUR, Society for Basic Urologic Research, 2005, 150-150
Skup
Fall Joint SBUR-ESUR Meeting, December 1-4, 2005.
Mjesto i datum
Miami Beach (FL), Sjedinjene Američke Države, 01.12.2005. - 04.12.2005
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
docetaxel combination therapies; weekly vs. q3w doses; differential scintigraphy
Sažetak
In distinguishing between weekly vs. q3w docetaxel doses applied to HRPC patients we used differential bone scintigrapy in patients with <20 lesions in bone by attributing to every lesion progression , stablization or remission status and thus recording the overall response in bone. We found that approach as exceedingly useful in differentiating progression from a stable disease of remission and thus the neccessity to change the therapy applaid,
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
